Target intelligence / Profile preview

Low affinity immunoglobulin gamma Fc region receptor III (FcγRIII)

Target
FcγRIII
Molecular classification
Receptor, Immunoglobulin-like receptor, Fc receptor
01

Overview

The low affinity immunoglobulin gamma Fc region receptor III (FcγRIII) is a cell surface receptor that binds the Fc region of IgG antibodies with low to intermediate affinity, primarily recognizing complexed or aggregated IgG. It exists in two main forms: transmembrane FcγRIIIa (on NK cells, macrophages, monocytes) associated with signaling adapters like the γ-chain for ADCC and cytokine production, and GPI-anchored FcγRIIIb (on neutrophils). It mediates immune effector functions including immune complex clearance, NK cell degranulation, and inflammation modulation. Structural studies show conserved hinge binding similar to other FcγRs but unique features in high-affinity variants; polymorphisms influence binding and disease susceptibility.

Other names
FcγRIIIa (transmembrane form, encoded by FCGR3A)FcγRIIIb (GPI-anchored form, encoded by FCGR3B)CD16a (for FcγRIIIa)CD16b (for FcγRIIIb)
02

Mechanism of action

Binding to IgG Fc region triggers ITAM-dependent signaling via associated γ-chain or CD247, leading to phosphorylation, PI3K activation, calcium influx, cytokine release, and cytotoxicity; low-affinity binding to monomeric or complexed IgG

03

Biological functions

Immune responseAntibody-dependent cellular cytotoxicity (ADCC)Immune complex clearanceSignal transductionNK cell activationCytokine productionDegranulation
04

Disease associations

InfectionInflammationAutoimmune disease (e.g., SLE)Cancer (via ADCC)
05

Safety considerations

Polymorphisms alter effector function and immune complex clearance, potentially leading to autoimmune disease risk (e.g., SLE) or reduced therapeutic antibody efficacyoveractivation may cause excessive inflammation or cytokine release
06

Interacting drugs

Therapeutic monoclonal antibodies (e.g., those engineered for enhanced FcγRIII binding, such as in immunotherapy; specific names not listed in sources but implied via glycan engineering)
07

Biomarkers

FCGR3A polymorphisms (e.g., rs396991, V158/F158 alleles affecting IgG binding affinity and ADCC efficacy)FCGR3B alleles (NA1/NA2 affecting glycosylation and function)

Beyond the preview

Go deeper on Low affinity immunoglobulin gamma Fc region receptor III (FcγRIII).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Low affinity immunoglobulin gamma Fc region receptor III (FcγRIII).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call